America makes 3% of its own medicine.

Accelbeam's patented microwave reactor technology enables domestic pharmaceutical manufacturing at 78-86% lower cost than conventional methods.

The only commercial-scale microwave-assisted synthesis platform. 16-jurisdiction patent portfolio. API output already sold to US pharmaceutical buyers.

The Problem

A National Vulnerability

The United States has outsourced pharmaceutical manufacturing to a critical degree, creating supply chain fragility, economic waste, and national security risks.

The Reformulation Gap

Every pharma company uses microwave chemistry in early drug development. But at scale, they must abandon microwave and reformulate for conventional heat - adding years and hundreds of millions in cost per drug.

$330M-$550M per drug

⚠

Manufacturing Crisis

US manufacturers produce only 3% of global API volume. 270 essential medicines are currently in shortage. Conventional domestic manufacturing cannot compete with offshore labor costs.

270 drugs in shortage

🛡

National Security Risk

When supply chains break, the US has no domestic fallback. Conventional API plants take 8-10 years and billions to build. The military cannot guarantee pharmaceutical supply from foreign-dependent chains.

8-10 years for a new plant

Clean Synthesis Technology

The Physics Breakthrough

Accelbeam solved the penetration depth problem that has kept microwave chemistry at bench scale for decades.

Volumetric Microwave Heating

Unlike conventional heating that heats vessel walls and waits for conduction, Accelbeam's CST delivers microwave energy directly to the entire reaction volume. 95% power uniformity at scale - vs. 40% for current microwave reactors.

Linear Scale-Up

Reaction kinetics remain identical regardless of volume. What works in a 100mL CEM vial works identically at 50L+ in Accelbeam's reactor. No reformulation required. Direct bench-to-commercial in the same technology.

Modular Reactor Stacks

Scale output by adding reactor stacks - not building bigger reactors or new plants. Deployable in weeks, not years. Enables distributed, rapid-response manufacturing.

Competitive Edge

Structural Advantages

Not incremental improvement. A paradigm shift in pharmaceutical manufacturing economics.

78-86%

Cost Reduction

Head-to-head across 3 chemical process types. Sales price below competitors' manufacturing cost.

10x

Faster Cycle Time

Under 1 hour vs. 12-24 hours for conventional batch. 10x asset utilization per reactor.

95%

Power Uniformity

Vs. 40% for current microwave reactors. Solves the physics problem that kept MAOS at bench scale.

60%

Lower Material Costs

5:1-10:1 solvent ratio vs. 20:1-50:1 conventional. Cleaner reactions, less waste, less purification.

200x

Capital Efficiency

Modular reactors deployed in 24 months. Conventional plants require 8-10 years and billions in capital.

Patent Jurisdictions

Global protection including US, EU, China, Japan, South Korea, India, and more. 2 granted, 14 pending.

Head to Head

Accelbeam vs. Traditional Manufacturing

Metric	Traditional Batch	Accelbeam CST	Investor Bottom Line
Cycle Time	12-24 hours	< 1 hour	10x asset utilization
Solvent Ratio	20:1 to 50:1	5:1 to 10:1	60% lower material costs
Heat Transfer	Surface-dependent	Volumetric / uniform	95% power uniformity
Development Tiers	3-4 pilot scales	Direct-to-commercial	$5M-$15M R&D savings/drug
Yield at Scale	Drops ~15% from lab	Maintains lab yield	Direct margin expansion
Purification	60% of mfg. OPEX	Fewer cycles needed	Massive DSP cost reduction
Facility Cost	$2B+ / 8-10 years	Modular / 24 months	200x capital efficiency

API Pipeline

32 Target Compounds

A two-phase approach targeting high-demand pharmaceutical APIs across multiple therapeutic classes.

Phase 1: Off-Patent

Immediate market opportunity. High-compatibility compounds with existing US demand and known shortage or stockpile needs.

Antiparasitic Antifungal CNS Cardiovascular Orphan

Phase 2: Patent Expiring

On-patent compounds with near-term patent expiration (2026-2032), representing the largest generic API opportunity in a decade.

Anticoagulant Oncology Metabolic Cystic Fibrosis Orphan

Intellectual Property

Global Patent Protection

Jurisdictions Filed

Patents Granted

Patents Pending

Platform Technology

Accelbeam's patent portfolio covers the core innovation that solves the microwave penetration depth problem - enabling commercial-scale pharmaceutical synthesis for the first time.

Coverage spans the United States, European Union, China, Japan, South Korea, India, Brazil, Canada, Australia, and additional jurisdictions - protecting the technology in every major pharmaceutical manufacturing market.

Clean chain of title with irrevocable transfer and extensive legal protections. No competitor has industrial-scale microwave reactor technology for API manufacturing.

Leadership

The Team

A focused team combining venture capital, pharmaceutical chemistry, and engineering expertise.

Kamden G.W. Burke

Chief Executive Officer

Managing Director, White Rhino Ventures. Leads corporate strategy, capital formation, and commercial development.

Stanislav Zhilkov

Chief Science Officer

Inventor of Clean Synthesis Technology. Architect of the microwave reactor platform and 16-jurisdiction patent portfolio.

Technical Team

Engineering & Science

Five dedicated technical members spanning reactor engineering, process chemistry, and pharmaceutical manufacturing.

Invest in the Future

Reshoring American
Pharmaceutical Manufacturing

Accelbeam is raising capital to deploy commercial-scale microwave reactor technology and bring pharmaceutical API production back to the United States.

Request Information Explore the Technology

Get in Touch

Interested in Accelbeam?

Whether you're an investor, pharmaceutical company, government agency, or potential partner - we'd like to hear from you. Complete the form and our team will respond promptly.

🏢

Accelbeam Inc.
Cheyenne, Wyoming